Table 2

Adjusted indirect comparisons of the efficacy of TNF╬▒ blocking agents in placebo controlled, randomised, double blind trials in patients with active rheumatoid arthritis with an incomplete response to methotrexate

Relative risk (95% CI)
ComparisonACR 20ACR 50
ACR, American College of Rheumatology; CI, confidence intervals.
Etanercept v adalimumab1.10 (0.57 to 2.12)2.60 (0.35 to 19.0)
Infliximab v adalimumab1.07 (0.66 to 1.73)1.35 (0.47 to 3.85)
Etanercept v infliximab1.03 (0.49 to 2.18)1.92 (0.22 to 17.0)